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Small cell lung cancer (SCLC) is an aggressive, rapidly metastasising tumour. Previously, we demonstrated the influence of CXCL12–
CXCR4 interaction on processes involved in metastasis and chemoresistance in SCLC. We show here that STAT3 is expressed in
both primary SCLC tumour tissues and SCLC cell lines. We investigated the function of STAT3 upon CXCL12 stimulation in SCLC
cell lines. Small cell lung cancer cell lines present constitutive phosphorylation of STAT3, and in the reference cell lines NCI-H69 and
NCI-H82 constitutive phosphorylation was further increased by CXCL12 stimulation. Further investigating this signalling cascade, we
showed that it involves interactions between CXCR4 and JAK2 in both cell lines. However CXCL12-induced adhesion to VCAM-1
could be completely inhibited by the JAK2 inhibitor AG490 only in NCI-H82. Furthermore, CXCR4 antagonist but not AG490
inhibited cell adhesion whereas both antagonisms were shown to inhibit growth of the cells in soft agar, indicating the central
involvement of this signalling in anchorage-independent growth of SCLC cells. Most interestingly, while using primary tumour material,
we observed that in contrast to non-small-cell lung cancer samples from primary tumour tissues, all analysed samples from SCLC
were strongly positive for tyrosine-phosphorylated STAT3. Taken together, these data indicate that STAT3 is constitutively
phosphorylated in SCLC and is important in SCLC growth and spreading thus presenting an interesting target for therapy.
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Small cell lung cancer (SCLC) is a highly fatal cancer due to early
and widespread metastasis and development of resistance to
chemotherapy (Hoffman et al, 2000). Despite initial sensitivity to
chemotherapy, SCLC almost invariably relapses, and the patients’
5-year survival rate is less than 5% (Chute, 2006). According to the
cancer homing theory, malignant cells of different solid tumours
(e.g. breast and prostate cancer) might use trafficking mechanisms
of haematopoietic stem cells to reach their distinct target tissues
(Wang et al, 2006). The chemokine receptor CXCR4 (CD184) and
its ligand CXCL12 (SDF-1a) are essential for the homing and bone
marrow interaction of haematopoietic stem cells (Peled et al, 1999,
2000; Ratajczak et al, 2006). Indeed, SCLC cell lines and primary
tumour cells express high levels of CXCR4 (Kijima et al, 2002;
Burger et al, 2003), and CXCR4 ligand CXCL12 is constitutively
expressed by bone marrow stromal cells (Muller et al, 2001).
Previously, we have shown that CXCR4 mediates important
functions for SCLC metastasis to stromal microenvironments, for
example adhesion of SCLC cells to immobilised extracellular
matrix proteins and stromal cells by activation of b1-integrins,
leading to cell adhesion-mediated drug resistance that protects
SCLC cells from chemotherapeutic treatment (Sethi et al, 1999;
Burger et al, 2003; Hartmann et al, 2005).
Stimulation with CXCL12 leads to activation of various path-
ways in SCLC cells, and CXCR4 has also been reported to activate
the JAK/STAT3 pathway (Vila-Coro et al, 1999; Ahr et al, 2005).
Signal transducers and activators of transcription (STAT) proteins
are latent transcription factors that become activated by
phosphorylation on a specific tyrosine residue by JAK-family
kinases (Darnell, 1997). Upon cytokine-induced receptor activa-
tion, JAKs phosphorylate monomeric STAT proteins, which
dimerise and translocate to the nucleus in a highly regulated way
leading to gene transcription (Reich and Liu, 2006). In many
cancers, STAT3 is constitutively activated, and aberrant STAT3
signalling is implicated as an important process in malignant
transformation (Bromberg et al, 1999) and induction of angio-
genesis (Niu et al, 2002). The tight association of STAT3 activation
with transformation and tumour progression makes it an
attractive molecular target for novel cancer therapeutics develop-
ment and many substances have been tested for their effect on
STAT3 (Deng et al, 2007). Although a link was found between
CXCR4 and STAT3 in different cells, such as haematopoietic
progenitor cells (Zhang et al, 2001) or a fibrosarcoma cell line
(Soriano et al, 2002), there are no reports on STAT3 signalling in
SCLC so far. Because of previously reported links between CXCR4
and JAK/STAT signalling and potential of this pathway to provide
drug targets, we were interested in whether this pathway is
involved in SCLC.
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STAT3 is strongly phosphorylated in tumour tissue samples from
patients with SCLC in comparison to samples from patients with
NSCLC (non-small-cell lung cancer). We report possible increased
CXCL12-induced STAT3 phosphorylation as well as lack of
CXCL12 effect on STAT3 phosphorylation depending on the cell
line. Further investigating this mechanism, we showed that JAK2/
STAT3 activation can be involved in anchorage-dependent cell
growth but is not involved in the adhesion of SCLC cells to
stromal cells.
MATERIALS AND METHODS
Cell culture, chemokines, antibodies, and inhibitors
Small cell lung cancer cell lines (NCI-H69, NCI-H82, NCI-H146,
NCI-H345, NCI-H446, NCI-H510A, and NCI-N592) and the murine
stromal cell line M2-10B4 were obtained from the American Type
Culture Collection (Manassas, VA, USA). The cells were main-
tained in RPMI-1640 medium containing 10% FCS, 1% penicillin,
and streptomycin (Gibco-BRL, Grand Island, NY, USA). Cell
viability was determined with Trypan blue staining. Synthetic
human CXCL12 and JAK2 antibodies were purchased from Upstate
Biotechnology (Lake Placid, NY, USA). Antibodies against STAT3
and phospho-STAT3 (Y705) were purchased from Cell Signalling
Technology Inc. (Beverly, MA, USA). Antibody against CXCR4 was
purchased from R&D Systems (Wiesbaden, Germany). Antibody
against CD56 was obtained from AbD Serotec (Duesseldorf,
Germany). Antibodies against integrin subunits were purchased
from Chemicon (Schwalbach, Germany). The inhibitor TN14003
was developed and kindly provided by N Fujii (Kyoto, Japan;
original publication, MRI, Molecular Cancer Therapeutics, 2003).
Pertussis toxin was obtained from Merck Biosciences (Darmstadt,
Germany). AG490 and anti-integrin antibodies were purchased
from Calbiochem (Bad Soden, Germany).
Nuclear extracts and western blotting
Small cell lung cancer cells were serum starved for 3h before
stimulation with CXCL12. Cells were preincubated with AG490 for
60min and stimulated with CXCL12. Cells (5 10
6) per sample
were lysed under hypotonic conditions to spare the nuclear
membrane (10mM HEPES (pH 8.0), 5mM KCl, 0.1mM EDTA,
0.1mM EGTA, 1mM Na3VO4,1 m M DTT, 0.5mM PMSF, protease
inhibitor mix (‘complete’; Roche Applied Science, Penzberg,
Germany). The nuclear fraction was separated by centrifugation
and was lysed subsequently (20mM HEPES (pH 8.0), 400mM NaCl,
1m M EDTA, 1mM EGTA, 2mM Na3VO4,1m M DTT, 0.5mM PMSF,
protease inhibitor mix).
Equal amounts of nuclear fractions were separated by 10%
SDS–polyacrylamide gel electrophoresis (PAGE) and transferred
onto nitrocellulose membranes. Immunostaining was performed
using antibodies against STAT3 or phospho-STAT3 (Y705). Bands
were visualised using horseradish peroxidase-conjugated second-
ary antibody and the enhanced chemiluminescence system
(Amersham Biosciences, Freiburg, Germany).
Co-immunoprecipitation
Cells (5 10
6) per sample were serum starved, stimulated with
CXCL12, centrifuged, and resuspended in 400ml lysis buffer
(20mM Tris-HCl (pH 8.0), 150mM KCl, 1mM EDTA, 1mM Na3VO4,
1m M PMSF, 1% Triton X-100, protease inhibitor mix). CXCR4
antibody was added overnight. Immunoprecipitates were collected
with 30ml Protein G sepharose beads (Amersham Biosciences).
They were washed three times with lysis buffer and once with PBS,
fractionated with SDS–PAGE and immunoblotted with a JAK2
antibody.
SCLC adhesion to immobilised collagen, fibronectin, and
VCAM-1
Adhesion assays to proteins of the extracellular matrix were
performed as described before (Hartmann et al, 2005). Briefly, 96-
well plates were coated with collagen type I (5mgml
 1), fibronectin
(10mgml
 1), and VCAM-1 (1.3mgml
 1) overnight. After washing
steps, CXCL12 was co-immoblised for 30min at room temperature
(8mgml
 1) and the wells were blocked for 60min with 1% tissue
culture BSA (Sigma, Munich, Germany) in PBS. Small cell lung
cancer cells were pretreated with AG490 (100mM) or DMSO (0.2%)
for 60min and added to the wells in quadruplicates and allowed to
adhere for 30min at 371C in adhesion buffer (HBSS buffered with
HEPES and supplemented with 0.5% BSA). The number of
adherent cells was determined using the CyQUANT Cell Prolifera-
tion Assay (Molecular Probes, Eugene, OR, USA) and fluorescence
was measured by a microtiter plate fluorometer (Spectra Max
Gemini XS; Molecular Devices, Munich, Germany). Five indepen-
dent experiments were performed.
SCLC cell adhesion to stromal cells
The murine stromal cell line M2-10B4 was seeded the day
before the assay onto 24-well plates at a concentration of
1.5 10
5 cells per well in RPMI-1640 supplemented with 10%
FCS. Small cell lung cancer cells were preincubated with TN14003
(100mgml
 1; 30min), AG490 (100mM; 60min), DMSO (0.2%;
60min), or left untreated and seeded on the stromal cell layer
at a concentration of 1 10
6 cells per well. After 3h at 371Ci n5 %
CO2, the wells were washed vigorously three times from four
directions with 1ml RPMI to remove non-adhering cells. The
remaining cells, including stromal cells and adhering SCLC cells,
were detached in trypsin/EDTA followed by three washing steps in
FACS medium (RPMIþ0.5% BSA). To distinguish SCLC cells
from stromal cells, we labelled them with an anti-CD56-PE
antibody for 30min at 41C and measured them by flow cytometry
(FACSCalibur; Becton Dickinson, Heidelberg, Germany). Thus,
increased proportion of CD56þ cells in the total cell suspension
results from pre-trypsin treatment adherent cells. Samples were
analysed in duplicates and each experiment was independently
performed five times.
Expression of integrin subunits and VCAM-1
Expression of integrin subunits was determined using mono-
clonal CD29, CD49a, CD49b, CD49c, CD49d, and CD49e anti-
bodies and the appropriate isotype controls (Becton Dickinson).
Small cell lung cancer cells were adjusted to a concentration
of 10
6 cells per ml in PBSþ0.5% BSA and stained with
saturated antibody concentrations for 20min at 41C. After
washing the cells twice, integrin expression was analysed by
flow cytometry.
Expression of soluble VCAM-1 in cell culture supernatants was
detected by an ELISA provided by R&D Systems (Quantikine
Mouse sVCAM-1 Immunoassay), according to the manufacturer’s
instructions.
Soft agar assay
Small cell lung cancer cells (1 10
4) were singularised in 2ml
RPMI-1640 containing 10% FCS and 0.3% agarose. Before pouring
the cells onto a bottom layer of 0.6% soft agar in 12-well plates,
TN14003 (100mgml
 1) or AG490 (100mM) were added. Untreated
cells and DMSO-treated cells (0.2%) were used as controls. The
cells were fed three times a week with fresh medium, containing
the appropriate inhibitors. Cell colonies were photographed after
2 weeks.
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Tissue samples of primary tumours from patients suffering from
SCLC (n¼10) and NSCLC (n¼13) were fixed in formalin and
embedded in paraffin. Sections (3mm) were dried, dewaxed in
xylene, and rehydrated through graded alcohol to water. Antigen
retrieval was carried out by boiling the samples at pH 6.1. Antigens
were stained using the alkaline phosphatase anti-alkaline phos-
phatase method (Dako, Hamburg, Germany) as described by
the manufacturer. Antibodies against STAT3 or phospho-STAT3
(Y705) were used at a concentration of 1:100.
Statistical analysis
For statistical analysis, the paired Student’s t-test for comparison
of two groups was used. Analyses were performed with the statistic
tool of Origin 7G (OriginLab Corporation, Northampton, MA,
USA).
RESULTS
Constitutive and inducible STAT3 in SCLC cell lines
To assess the levels of phosphorylated STAT3 in SCLC, we
prepared and examined nuclear extracts from seven unstimulated
SCLC cell lines by western blot analysis using an anti-phospho-
STAT3 antibody. As a control, total nuclear STAT3 was stained.
We found constitutive STAT3 phosphorylation in most of the
investigated cell lines, but at variable levels. The cell line NCI-
H510A displayed exceptionally strong constitutive STAT3 phos-
phorylation whereas NCI-H69 displayed the lowest level with slight
to undetectable constitutive expression (Figure 1A). As NCI-H69
and NCI-H82 are the most commonly investigated SCLC cell lines
and displayed rather weak constitutive activation, we further used
these two cell lines to determine whether CXCL12 is able to directly
activate JAK2/STAT3 signalling pathways in SCLC cells. To do
so we measured levels of tyrosine-phosphorylated STAT3 in
nuclear extracts after CXCL12 treatment. STAT3 exists in different
isoforms; STAT3a is the most commonly described so far. STAT3a
was phosphorylated upon CXCL12 stimulation in a time-depen-
dent manner with a maximum after 10min, still showing a strong
signal after 30min, reduced cytosolic effect might be the result of
the low representation of STAT3 in this pool (Figure 1B). CXCL12-
induced tyrosine phosphorylation of STAT3 could be observed in
SCLC cells lines NCI-H69, NCI-H82, NCI-H119, NCI-H173, and
NCI-H446, but not in NCI-N592 (Figure 1C). High expression of
CXCR4 has however been described in NCI-N592 (Burger et al,
2003) underlying the heterogeneity of SCLC cell lines and reflecting
heterogeneity among SCLC diagnosed tumours themselves.
To directly analyse the association of JAK2 with CXCR4 upon
CXCL12 stimulation, we performed co-immunoprecipitation
assays with NCI-H69 and NCI-H82. In both cell lines, constitutive
association of JAK2 with CXCR4 was observed, however with
a lower intensity for NCI-H69. Association of JAK2 with CXCR4
increased upon stimulation with CXCL12 with a maximal
association observed after 15min (Figure 1D). In contrast, NCI-
H82 showed a strong constitutive association of JAK2 to CXCR4
that could not be further increased by CXCL12 stimulation. The
observation of two bands of phosphorylated JAK-2 was unexpected
and is likely to result from protein degradation.
Expression and functions of b1-integrins in SCLC cell lines
NCI-H69 and NCI-H82
We investigated further the differences between NCI-H69 and NCI-
H82 activation focusing on another family of proteins: integrins.
Integrins form a family of heterodimeric proteins (a- and b-
subunits). They are cell adhesion molecules that mediate cell–
extracellular matrix as well as cell–cell interactions. It has been
demonstrated that b1-integrin signalling leading to malignant cell
adhesion is involved in resistance of SCLC cells against
chemotherapy (Sethi et al, 1999). Both SCLC cell lines analysed,
NCI-H69 and NCI-H82, were positive for b1-integrin and negative
for a1-, a2-, and a3-integrins, but differed in expression of a4- and
a5-subunits. In contrast to NCI-H69 that did not express any a5,
NCI-H82 was positive for this subunit. Integrin a4 was expressed
in NCI-H82 more abundantly than in NCI-H69 (Figure 2).
Interestingly, a4-b1 integrin, also called VLA4 (alpha4-beta1
integrin), is known to be involved in cell-adhesion mediated drug
resistance of tumours (Sanz-Rodrı ´guez et al, 2001).
Adhesion of NCI-H82 to VCAM-1 is dependent on JAK2
Previously, we have shown that immobilised CXCL12 induces
VLA-4-mediated adhesion of SCLC cell lines to immobilised
VCAM-1 and fibronectin, which could be inhibited by pertussis
toxin and rho-kinase inhibitors (Burger et al, 2003; Hartmann
et al, 2005). Here we investigated the influence of the JAK2/STAT3
pathway on this process. Proteins of the extracellular matrix and
CXCL12 were co-immobilised on 96-well plates and the adhesion
rate of SCLC cells was determined.
The cell line NCI-H82 showed strongest CXCL12-mediated
adhesion to VCAM-1, which could be fully reversed by preincuba-
tion with JAK2 inhibitor AG490 (Figure 3A). Adhesion of this cell
H173 H119 H69 H446 N592 NCI-      H82
NCI-H82 NCI-H69
JAK2
CXCR4
CXCL12 – + – + – + – + – + – +
P-STAT3
P-STAT3 
P-STAT3 
P-STAT3 
P-STAT3 
NCl- H82 H69 H416 H345 H510A H446 N592
STAT3
CXCL12
Nucleus:
Cytosol:
0 min 5 min 10 min 20 min 30 min
CXCL12 0 min 5 min 15 min 0 min 5 min 15 min
A
B
C
D
Figure 1 Characterisation of JAK2/STAT3 pathway in SCLC cells.
Nuclear extracts of untreated SCLC cells were analysed by western blot
analysis and showed STAT3 phosphorylation at different degrees. (A)
CXCL12-induced phosphorylation of STAT3 occurred in a time-
dependent manner, as observed in western blot analysis with nuclear
extracts of NCI-H69 treated with 100ngml
 1 CXCL12 (B). All tested cell
lines but NCI-N592 showed induction of STAT3 phosphorylation by
CXCL12 stimulation (C). JAK2 was stained in a western blot analysis
following co-immunoprecipitation with a CXCR4 antibody after stimulating
NCI-H69 (left panel) and NCI-H82 (right panel) with 100ngml
 1 CXCL12
for the indicated period of time (D). Each blot shown is representative for
at least three independent experiments.
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influence by AG490. Significant increases by CXCL12 stimulation
were reached only in presence of VCAM-1 (P¼0.002), this
induction was significantly decreased after treatment with
AG490. In contrast, CXCL12 induced NCI-H69 cell adhesion to
collagen (P¼0.065) whereas CXCL12-mediated adhesion to
VCAM-1 and fibronectin was lower (P¼0.095) and significantly
reduced compared to results obtained for NCI-H82 cells
(P¼0.002). This correlates to the VLA-4 expression levels of the
different cell lines, and the low adhesion of NCI-H69 can be
explained by the low VLA-4 expression of this cell line. Basal level
of adhesion is markedly different in both cell lines. We could not
detect any inhibitory influence of AG490 on CXCL12-triggered
adhesion of NCI-H69 cells (Figure 3B). To compare directly the
treatment effects in both cell lines, we expressed the results in
function of the basal levels of adhesion obtained with control BSA
treatment. Results are shown in the Table 1 and illustrate
observations described previously, further showing the differences
after treatment by AG490 in each cell lines (shaded results).
Adhesion of SCLC cell lines to the stromal cell line
M2-10B4
Previously we demonstrated that VLA-4 blocking by anti-a4
antibody and CXCR4 blocking by the antagonist TN14003 inhibited
SCLC cell adhesion to stromal cells (Hartmann et al, 2005).
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Figure 2 Expression of integrin subunits in SCLC cell lines. Fluorescence histograms depicting the expression of b1-integrin (CD29) and a1-, a2-, a3-,
a4-, a5-integrin (CD49a, CD49b, CD49c, CD49d, CD49e) subunits by SCLC cell lines NCI-H69 and NCI-H82 are shown by black lines. The respective
isotype controls are represented by grey shaded histograms.
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Figure 3 Adhesion to extracellular matrix proteins. Relative adhesion rates of NCI-H82 (A) and NCI-H69 (B) to VCAM-1, fibronectin and collagen I
measured after 30min are shown for untreated controls, cells stimulated with co-immobilised CXCL12 (8mgml
 1), cells preincubated with AG490 (60min,
100mM), and cells that were both preincubated with the inhibitor and stimulated by CXCL12. Error bars represent s.e.m. Differences were accepted
as significant when Po0.05 (*), n¼5, each experiment in quadruplicates.
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peptide-derived CXCR4 antagonist; TN14003 is serum stable and
more specific variant of T140 (Tamamura et al, 2004). In addition
to CXCL12, soluble VCAM-1 is secreted by M2-10B4: using ELISA
we determined that at least 2.38±0.66ngml
 1 VCAM-1 was
present in our supernatants (four independent assays in dupli-
cates) as already observed (Hartmann et al, 2005). Due to the
observed AG490-mediated inhibition of NCI-H82 adhesion to
VCAM-1 and the detected VCAM-1 secretion of stromal cells, we
investigated if AG490 treatment inhibits NCI-H69 and NCI-H82
adhesion to stromal cells. However, in the more complex
environment of stromal interaction, JAK2 blockage alone was
not able to inhibit the SCLC cell adhesion to the stroma, whereas
CXCR4 inhibition by TN14003 was fully efficient (Figure 4),
demonstrating activation of branched pathways triggered by
CXCL12 binding to CXCR4.
Importance of the CXCR4 and JAK2/STAT3 pathway in
anchorage-independent growth
The anchorage-independent growth of SCLC cells was determined
in a soft agar assay (Missale et al, 1998). In absence of inhibitors
and in the DMSO control, the cells were able to build large
aggregates in the soft agar during the 2-week observation period.
In contrast, there was no proliferation in the presence of the
CXCR4 inhibitor TN14003, which suggests a contribution for this
chemokine receptor in this process. There was also a complete
inhibition by the JAK2 inhibitor AG490, suggesting importance of
this pathway in anchorage-independent growth (Figure 5). In the
first week, both the inhibited cells and controls looked quite
similar under the microscope except for the fact that the inhibited
ones did not proliferate. However, after 7–10 days cells inhibited
with TN14003 and AG490 began to change their morphology. They
became rounder, sharper circumscribed, and finally darker in
appearance than the controls.
STAT3 is phosphorylated in primary tumours from
patients with SCLC
To assess the relevance of these observations in a pathophysio-
logical context, we investigated STAT3 phosphorylation in SCLC
and compared it to NSCLC. Tissue samples of primary tumours
from patients suffering from SCLC (n¼10) and NSCLC (n¼13)
were stained with anti-phospho-Tyr705 STAT3 and anti-STAT3
antibodies in immunohistochemistry. Samples from patients
suffering from SCLC (10 out of 10) were found to be strongly
positive for phosphorylated STAT3, whereas samples from patients
suffering from NSCLC (13 out of 13) showed significantly
phosphorylated STAT3 only in basal layers of the respiratory
epithelia and alveolar macrophages, but not within the tumour
tissue. For the detection of unphosphorylated STAT3, samples
from both SCLC and NSCLC were stained equally using an anti-
STAT3 antibody (Figure 6).
DISCUSSION
The JAK2/STAT3 pathway is involved in various signalling
cascades, including signalling of receptor tyrosine kinases and
G-protein-coupled receptors. Activation of the JAK/STAT pathway
is linked to proliferation, and constitutive activation of both JAK2
and STAT3 is described to be important in malignant transforma-
tion and tumourigenesis (Bromberg et al, 1999; Levy and Darnell,
2002). STAT3 is focusing more and more interest in cancer therapy
as it is often overactivated in cancer. The constitutively active JAK2
mutant V617F is found in many patients with myeloproliferative
Table 1 Data are extracted from Figure 3A and B, and represent normalization in reference to basal adhesion in presence of control BSA treatment
BSA Collagen Fibronectin VCAM-1
Fold increase compared to no treatment + + + + + + + + + + + +
CA C A CA C AC AC ACA C A
X G XG X G XG X G XG X G XG
C 4 C4 C 4 C4 C 4 C4 C 4 C4
L 9 L9 L 9 L9 L 9 L9 L 9 L9
12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0
H69 0.8 1.2 1.4 2.1 1.0 2.4 1.4 1.0 1.3 1.6 1.4 1.8
H82 0.9 1.0 1.1 1.2 0.8 1.2 1.4 1.1 1.3 1.9 1.0 1.0
Results of interest are highlighted in grey.
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Figure 4 Adhesion to stromal cell line M2-10B4. NCI-H82 (A) and NCI-H69 (B) were allowed to adhere to M2-10B4 cells for 3h after pretreatment
with AG490 (100mM, 60min) or TN14003 (100mgml
 1, 30min), respectively, then submitted to vigorous washes to remove non-adherent cells from the
medium, the whole-cell complex was then submitted to trypsinisation to put it in suspension before assessment of the proportion of each cell type by FACS
(n¼3).
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sdiseases (Levine and Gilliland, 2007), and constitutively phos-
phorylated STAT3 is found in many solid tumours and
haematopoietic malignancies (Lim and Cao, 2006). The chemokine
receptor CXCR4 was described to activate the JAK2/STAT3
pathway in different cell lines (Vila-Coro et al, 1999; Soriano
et al, 2003; Opdam et al, 2004; Moriguchi et al, 2005) and the
intracellular domains responsible for JAK2 binding have been
discovered by mutational analysis (Ahr et al, 2005). Until now,
there has been no report on the activation of the JAK/STAT
pathway in SCLC.
In this study, we demonstrate that STAT3 is strongly
phosphorylated in primary tumour tissues from patients with
SCLC indicating that this pathway might be relevant in patho-
physiological processes involved in SCLC. In contrast to this, the
primary tumour tissue samples from patients with NSCLC did not
show any strong STAT3 activation within the tumour tissue. In
NSCLC samples, only alveolar macrophages and basal layers of
respiratory epithelia showed strongly phosphorylated STAT3, cell
types already known to show phosphorylation of STAT3 due to
their proliferative capacity. Reports on constitutive phosphory-
lation of STAT3 in some NSCLC cell lines (Song et al, 2003) and
lung adenocarcinomas (Gao et al, 2007) are not in contrast with
our observation because they reported relatively low percentages
of strong phosphorylation and the STAT3 phosphorylation was
A
E
B
F
C
G
D
H
NCI-H82
NCI-H82 + TN14003
NCI-H82 + DMSO
NCI-H82 + AG490 NCI-H69 + TN14003
NCI-H69 + DMSO
NCI-H69 + AG490
NCI-H69
Figure 5 Anchorage-independent growth in soft-agar. SCLC cells NCI-H82 (A, B and E, F) and NCI-H69 (C, D and G, H) were singularised, put in a
0.3% agarose gel and observed in the absence (A, C) or presence of TN14003 (100 mgml
 1)( E, G) and AG490 (100 mM)( F, H). Appropriate controls
were done with DMSO (B, D) to rule out any involvement of this solvant in the observed results. Characteristic cell aggregates were photographed after 14
days (n=3).
AB
CD
Figure 6 Representative immunohistochemical staining of primary tumour samples from 10 patients with SCLC (A and C) and 13 patients with NSCLC
(B and D). Slides were stained with phospho-Tyr705-STAT3 antibody (upper row: A and B) and STAT3 antibody (inferior row: C and D), respectively.
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smainly related to mutations in the EGFR kinase domain and IL-6
production.
Small cell lung cancer tumour and cellular models for in vitro
investigation have been shown to be heterogeneous (Carney et al,
1985); however, some common features can be described: all
analysed SCLC cell lines showed constitutive STAT3 phosphoryla-
tion, however to various degrees. In addition to the constitutive
activation of STAT3, we were able to demonstrate that stimulation
of SCLC cell lines with CXCL12 increased the STAT3 phosphory-
lation in all the cell lines but one. Interestingly, we found only the
a-isoform of STAT3 to be phosphorylated upon stimulation. Both
isoforms are thought to have different functions and to induce
transcription of different genes (Chakraborty et al, 1996; Maritano
et al, 2004), but functional differences are poorly understood so
far. Nevertheless, exclusive STAT3a phosphorylation after IL-6 or
IL-10 stimulation has been shown in different cellular models
(Maritano et al, 2004). Previous studies that describe a CXCR4-
mediated STAT3 activation do not differentiate between the
isoforms so our results are a new hint that cytokine activation
targets a-isoform phosphorylation. To focus on this point, we used
two SCLC cell lines that showed only low constitutive STAT3
phosphorylation but a clearly inducible phosphorylation in
response to CXCL12: NCI-H82 and NCI-H69. The association of
JAK2 to CXCR4 was induced by CXCL12 in NCI-H69. In NCI-H82
cell line, the constitutive association of JAK2 and CXCR4 is
stronger but cannot be further increased. This seems to go along
with a stronger activation of NCI-H82 in functional assays. For
example, NCI-H82 showed a higher basal adhesion level in
comparison to NCI-H69, and NCI-H82 built larger aggregates in
soft agar assays.
CXCR7 is a recently described second receptor for CXCL12 and
was shown to promote lung cancer growth in vivo (Miao et al,
2007) but this receptor might rather modulate CXCR4-mediated
responses than act as an independent CXCL12 receptor
(Hartmann et al, 2008). To assess a potential involvement of
CXCR7 in the results observed here, we investigated CXCR7
expression at the surface of NCI-H69, NCI-H82, and NCI-N592,
with a particular interest for NCI-N592, where the lack of STAT3
activation upon CXCL12 stimulation could be explained by a
CXCR7 scavenging of CXCL12. Expression was shown to be absent
or very low in NCI-H82 and NCI-N592 but high in NCI-H69 (data
not shown); however, consistent inhibition of CXCL12 activation
in NCI-H69 by TN14003 seems to rule out any major involvement
of CXCR7 in this mechanism of activation.
To further evaluate the functional relevance of the biochemical
proof of CXCL12-induced activation of JAK2 and STAT3 and a
constitutive STAT3 phosphorylation in vivo, we analysed the effect
of the JAK2 inhibitor AG490 on adhesion mediated by CXCR4- and
anchorage-independent cell growth. Only a few studies demonstrate
an influence of JAK2 in cytokine-stimulated adhesion. One study
demonstrated almost complete abrogation of CXCL12-induced
adhesion of T cells to VCAM-1 by AG490 (Garcı ´a-Bernal et al,
2005). In accordance with these data on haematopoietic cells, we
observed a complete inhibition of the CXCL12-induced adhesion
of the SCLC cell line NCI-H82 to VCAM-1 by AG490. In contrast,
CXCL12-induced VCAM-1 adhesion of NCI-H69 was much lower,
due to lower a4-integrin expression, and we could not demonstrate
an AG490 influence. In addition, although the bone marrow
stromal cell line M2-10B4 expresses high amounts of CXCL12 and
VCAM-1, we could not abrogate SCLC adhesion to M2-10B4 by
AG490. This suggests compensating mechanisms or other more
dominant pathways in this complex adhesion model. Besides
adhesion, anchorage-independent growth is a major function that
promotes tumour growth and metastasis. Anchorage-independent
growth was reported to be dependent on CXCR4 by many groups
and for numerous malignancies (Ratajczak et al, 2006; Wang et al,
2006). We analysed anchorage-independent growth in a soft agar
assay (Missale et al, 1998), where cells proliferate without cell or
surface contacts and must overcome contact inhibition. Consis-
tently with reports on other malignancies (Sehgal et al, 1998;
Huang et al, 2005), we demonstrate a complete inhibition of soft
agar proliferation in the cell lines NCI-H69 and NCI-H82 by
blocking JAK2 or CXCR4 with the inhibitors AG490 and TN14003,
respectively.
Taken together, we show high constitutive STAT3 phosphorylation
in primary tumour samples from patients with SCLC but not from
NSCLC, and constitutive and CXCL12-dependent activation of the
JAK2/STAT3 pathway in SCLC cell lines. Furthermore, we have shown
here, that although STAT3 is commonly implicated in SCLC biology,
at least two different upstream pathways dependent or independent of
CXCR4 can be involved in its phosphorylation. This is of particular
interest in drug development strategies as both CXCR4 and STAT3
antagonisms have been proposed as broad spectrum target in cancer
therapy (Wang et al, 2006; Germain and Frank, 2007; Ruffini et al,
2007). We show here that SCLC drug development should take into
account CXCR4/STAT3 linkage to target more specifically the
malignant cells; although JAK2/STAT3 seems to have a dominant
function in anchorage-independent cell proliferation, it has a minor
function in adhesive processes of SCLC cells where CXCR4 antagonists
should prove more efficient. Besides CXCR4 antagonists that are
currently investigated in an in vivo model for SCLC, STAT3 inhibitors
on its own or in combination with CXCR4 inhibitors will be very
interesting to consider as therapeutic option for the treatment of
patients with SCLC.
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